Cellular reactive oxygen species production (ROS production)

Cellular reactive oxygen species (ROS) production refers to the generation of highly reactive oxygen-containing molecules, such as superoxide anions, hydrogen peroxide, and hydroxyl radicals, which occur as natural byproducts of mitochondrial metabolism or through specialized enzymes like NADPH oxidases (NOX). While low levels of ROS are critical for physiological signal transduction and the innate immune response, an imbalance between ROS production and the cell's antioxidant capacity leads to a state of oxidative stress (Pizzino et al., 2017, Oxidative Medicine and Cellular Longevity). This state results in the oxidative modification and damage of lipids, proteins, and DNA, serving as a fundamental driver in the pathogenesis of chronic diseases including atherosclerosis, Parkinson's disease, and various cancers (Murphy et al., 2022, Nature Metabolism). In drug discovery, 'Cellular ROS production' is typically treated as a phenotypic outcome or a pathological process rather than a single molecular target. Pharmacological interventions aim to restore redox homeostasis by either neutralizing reactive species directly or by modulating specific molecular targets within the redox network, such as activating the Nrf2 transcription factor to upregulate antioxidant enzymes or inhibiting NOX isoforms to prevent excessive ROS generation (Sies & Jones, 2020, Nature Reviews Molecular Cell Biology). However, the therapeutic application of antioxidants has faced significant challenges in clinical trials, often due to the lack of spatial and temporal specificity, which can inadvertently disrupt essential redox-dependent signaling pathways required for normal cellular function.

Other names

Oxidative stressReactive oxygen species generationRedox stressOxidative damageROS signaling

Therapeutic strategies targeting this process include the direct scavenging of free radicals, the inhibition of ROS-generating enzymes such as NADPH oxidase (NOX) or xanthine oxidase, and the pharmacological activation of endogenous antioxidant defense systems, primarily through the Nrf2/KEAP1 signaling pathway (Sies et al., 2017, Nature Reviews Molecular Cell Biology).